Cellectis has appointed Mathieu Simon to as interim chief medical officer, taking over the role from Loan Hoan-Sayag, who has left the French biopharmaceutical group to “pursue other opportunities”.
As current executive vice president and chief operating officer, Simon was previously chief executive officer of former subsidiary Cellectis Therapeutics has been “instrumental in the strategic and operational management of all therapeutic activities”.
His other roles include senior vice president, global pharma operations for Pierre Fabre and has held numerous senior roles with Wyeth Pharmaceuticals, before it was acquired by Pfizer for $68bn back in 2009.